Journal article
Fetal malformations in successive pregnancies in Australian women with epilepsy
F Vajda, T O'Brien, J Graham, A Hitchcock, P Perucca, C Lander, M Eadie
Epilepsy and Behavior | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2022
Abstract
Objectives: To utilize data from the Australian Register of Antiepileptic Drugs in Pregnancy (APR) to determine the hazard of fetal malformation in the subsequent pregnancy or pregnancies in women with epilepsy following a pregnancy associated with a fetal malformation, and to identify factors relevant to the hazard. Results: There was a 7.4% initial pregnancy fetal malformation rate. The subsequent pregnancy malformation rate was 4.2% if there was no initial pregnancy malformation, but 21.2% if there was an initial pregnancy malformation (O.R. = 6.1448, 95% C.I. 2.3396, 16.1386). For pregnancies where antiseizure medication (ASM) therapy was unchanged between pregnancies (N = 196), the init..
View full abstractGrants
Awarded by Sanofi
Funding Acknowledgements
We are grateful to professional and lay colleagues and bodies for referring patients to the APR, and to the Scientific Advisory Board and the Ethical Research Committees of St. Vincent's Hospi-tal, Monash Medical Centre, the Royal Melbourne Hospital and other institutions for their successive ethics oversight of the APR. The Epilepsy Society of Australia, The Royal Melbourne Hospital Neuroscience Foundation, Epilepsy Australia, the NHMRC and the pharmaceutical companies Sanofi-Aventis, UCB Pharma, Janssen-Cilag, Novartis, Sci-Gen, Eisai and Genzyme have provided financial support toward maintaining the APR at various stages of its existence.